Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02583477 · ClinicalTrials.gov registry record · Phase 1
Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02583477 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 23 participants.
The verdict
NCT02583477, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations (with chemotherapy or AZD5069) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
- DRUG MEDI4736 in combination with nab-paclitaxel and gemcitabine
- DRUG MEDI4736 in combination with AZD5069
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-03-25 |
| Est. Completion | 2018-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02583477
The ClinicalTrials.gov registry entry for NCT02583477 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MEDI4736 in combination with nab-paclitaxel and gemcitabine is the first listed.
NCT02583477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02583477 about?
NCT02583477 is a clinical study titled "Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma". A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations (with chemotherapy or AZD5069) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
What is the current status of trial NCT02583477?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-03-25. Estimated completion is 2018-07-09.
What interventions are being tested in trial NCT02583477?
The interventions under investigation include: MEDI4736 in combination with nab-paclitaxel and gemcitabine (DRUG), MEDI4736 in combination with AZD5069 (DRUG).
Who is sponsoring clinical trial NCT02583477?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.